YS Biopharma (YSBPW) Stock Price, News & Analysis

Company Overview

YS Biopharma Co., Ltd., a biopharmaceutical company, engages in discovering, developing, manufacturing, and commercializing of vaccines and therapeutic biologics for infectious diseases and cancer. It develops a proprietary PIKA immunomodulating technology platform and a series of preventive and therapeutic biologics targeting Rabies, Coronavirus, Hepatitis B, Influenza, and Shingles. It operates in China, the United States, Singapore, the United Arab Emirates, and the Philippines. The company was founded in 2002 and is based in Beijing, China.

Key Stats

• Today's Range: $0.05 to $0.05
• 50-Day Range: $0.04 to $0.10
• 52-Week Range: $0.01 to $0.10
• Volume: 4,001 shs
• Average Volume: 37,227 shs
• Market Capitalization: N/A
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

YSBPW Stock Analysis - Frequently Asked Questions

How have YSBPW shares performed this year?

YS Biopharma's stock was trading at $0.0380 on January 1st, 2024. Since then, YSBPW stock has increased by 21.1% and is now trading at $0.0460.
View the best growth stocks for 2024 here.

How do I buy shares of YS Biopharma?

Shares of YSBPW stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Biotechnology
• Sub-Industry: N/A
• Current Symbol: NASDAQ:YSBPW
• CUSIP: N/A
• CIK: 1946399
• Web: www.yishengbio.com
• Phone: 86-10-8920-2086
• Fax: N/A
• Employees: 865
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: $560.76 million
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: N/A
• Free Float: N/A
• Market Cap: N/A
• Optionable: Not Optionable
• Beta: N/A